EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Phenotyping Overactive Bladder – Part 2: Can Management be Improved by Phenotyping, and Targeting Therapy According to Urgency Type and Other Characteristics? ICI‐RS 2025

Michel Wyndaele iD, Michael Samarinas iD, Apostolos Apostolidis iD, D Carolina Ochoa iD, Giovanni Mosiello iD, Brigitte Schurch iD, Pradeep Tyagi iD, Alan Wein iD, Paul Abrams iD, John E Speich iD

Neurourology and Urodynamics · 2026

DOI: 10.1002/nau.70171 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neurourology and Urodynamics, 2026. Verfasst von Michel Wyndaele und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Medical Center Utrecht, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Management of overactive bladder (OAB) has a stepwise approach in adults and children. This does not account for individual patient variations, which may explain suboptimal outcomes in many patients. Distinct OAB profiles, based on patient characteristics, symptoms, urodynamic findings and imaging have been discussed in Part 1. Personalized treatment and escalation pathways based on OAB profiling may lead to faster OAB symptom control and quality of life improvement, reduced cumulative side effects and costs, and improved treatment adherence.

Methods

A Think Tank at the International Consultation on Incontinence‐Research Society (ICI‐RS) 2025 discussed the question, “Can OAB management be improved by phenotyping, and targeting therapy according to urgency type and other characteristics?” The group discussed the current literature on this topic and developed a list of research questions and strategies to help shape the future of the field.

Results

Tailored combination of antimuscarinics and/or beta3 agonists, with botulinum toxin A (BTX‐A) and/or sacral nerve stimulation (SNS) was considered a high priority research topic. Profile‐based individual treatment selection and delivery protocols for BTX‐A and SNS are potential means to improve outcomes, as is the early escalation to BTX‐A and SNS in the treatment pathway of both adults and children. Finally, phenotype‐based treatment requires tight treatment outcome follow‐up and possible adjustment (including re‐phenotyping) for which tools need to be developed.

Conclusion

Development and validation of a patient‐based flow‐chart to replace the current stepwise approach in OAB management will allow tailored treatment, aimed to improve therapeutic success, and to reduce side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder, OveractiveHumansPhenotypeMuscarinic AntagonistsAdrenergic beta-3 Receptor AgonistsBotulinum Toxins, Type AElectric Stimulation TherapyTreatment OutcomeUrodynamics

Stichwörter der Autor:innen

antimuscarinicsbeta3 agonistsonabotulinum toxin Aoveractive bladderphenotypesacral nerve stimulation

Substanzen

Muscarinic AntagonistsAdrenergic beta-3 Receptor AgonistsBotulinum Toxins, Type A

Autor:innen und Institutionen

  • Department of Urology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • 2nd Department of Urology, Aristotle University, Thessaloniki, Greece.
  • Bristol Urological Institute, Bristol, UK.
  • Department of Urology, Campus Bio-Medico University of Rome, Rome, Italy.
  • Service de Neuroréhabilitation, CHUV, Lausanne, Switzerland.
  • Department of Urology, University of Pittsburgh, Pittsburgh, PA, USA.

ORCID-Profile: Michel Wyndaele, Michael Samarinas, Apostolos Apostolidis, D Carolina Ochoa, Giovanni Mosiello, Brigitte Schurch, Pradeep Tyagi, Alan Wein, Paul Abrams, John E Speich

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Wyndaele, M., Samarinas, M., Apostolidis, A., Ochoa, D. C., Mosiello, G., Schurch, B., Tyagi, P., Wein, A., Abrams, P., & Speich, J. E. (2026). Phenotyping Overactive Bladder – Part 2: Can Management be Improved by Phenotyping, and Targeting Therapy According to Urgency Type and Other Characteristics? ICI‐RS 2025. Neurourology and Urodynamics. https://doi.org/10.1002/nau.70171

Vancouver

Wyndaele M, Samarinas M, Apostolidis A, Ochoa DC, Mosiello G, Schurch B, et al. Phenotyping Overactive Bladder – Part 2: Can Management be Improved by Phenotyping, and Targeting Therapy According to Urgency Type and Other Characteristics? ICI‐RS 2025. Neurourology and Urodynamics. 2026. doi:10.1002/nau.70171

BibTeX
@article{Wyndaele2026,
  author = {Wyndaele, Michel and Samarinas, Michael and Apostolidis, Apostolos and Ochoa, D Carolina and Mosiello, Giovanni and Schurch, Brigitte and Tyagi, Pradeep and Wein, Alan and Abrams, Paul and Speich, John E},
  title = {Phenotyping Overactive Bladder – Part 2: Can Management be Improved by Phenotyping, and Targeting Therapy According to Urgency Type and Other Characteristics? ICI‐RS 2025},
  journal = {Neurourology and Urodynamics},
  year = {2026},
  doi = {10.1002/nau.70171}
}
Kostenlos starten →